Targeting colorectal cancer cell lines with gefitinib (a tyrosine kinase inhibitor) or oxaliplatin revealed that nuclear PKM2 contributed to therapeutic resistance in vitro and in vivo models of colorectal cancer [17, 18]. This evidence concerns the gene PKM and colorectal cancer.